Recent developments in ocular nanotherapy: An editorial

Recent developments in ocular nanotherapy: An editoria

Lactoferrin and cancer in different cancer models

Lactoferrin (Lf) is a multifunctional protein and an essential element of innate immunity. Cancer is a major killer in today's world accounting for around 13% of all deaths according to the World Health Organisation (W.H.O.). The five most common forms of cancer include lung, colorectal, stomach, liver and breast cancer. Lactoferrin is a natural forming iron-binding glycoprotein with antibacterial, antioxidant and anti-carcinogenic effects. It is produced in exocrine glands and is secreted in many external fluids as a first line of defence. Lactoferrin also has the capacity to induce apoptosis and inhibit proliferation in cancer cells as well as restore white and red blood cell levels after chemotherapy. This review focuses on the therapeutic effect bovine sourced lactoferrin has on various forms of cancer in various models. It also focuses on the benefits of 3D in vitro cell culture. 3D cell culture has vast advantages over 2D models including demonstration of realistic therapeutic results and heightened resistance that 2D models fail to display

Corrigendum to “Brain targeted PLGA nanocarriers alleviating amyloid-Β expression and preserving basal survivin in degenerating mice model” [Biochim. et Biophys. Acta (BBA) – Mol. Basis Dis. 1852 (11) (November 2015) 2423–2431] (Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2015) 1852(11) (2423–2431), (S0925443915002422), (10.1016/j.bbadis.2015.08.015))

The authors regret that the printed version of the above article contained a number of errors. The authors apologize for this unintentional human error (due to the complexity of the data) and state that this does not change the scientific conclusions of the article in any way. The correct and final version follows. The authors would like to apologize for any inconvenience caused. Corrected images for Fig. 4A, B and C are given below. Fig. 4A [Figure presented] Fig. 4B [Figure presented] Fig. 4C [Figure presented

Corrigendum to Upregulation of sodium iodide symporter (NIS) protein expression by an innate immunity component: Promising potential for targeting radiosensitive retinoblastoma [Exp. Eye Res. 139 (2015) 108e114] (Experimental Eye Research (2015) 139 (108–114), (S0014483515002377), (10.1016/j.exer.2015.07.011))

The printed version of the above article contained errors in Figure 1.C. Due to an unintentional human error, in the first Apo-bLf row, the first two histograms have been interchanged and hence placed in the wrong columns. Also, the last two histograms of FebLf and Native-bLf (75 nM concentration) samples have been interchanged. This error happened while compiling the image panels for the Figure 1.C. All the first 3 histograms in the first column of the Figure represent same control sample's histogram. The rest of the histograms belong to the treated samples. We state further that this correction does not change the Figure legend and the study conclusions of the article in any way. The correct and final version of the Figure 1.C follows. The authors apologise for any inconvenience caused. [Figure presented

Preface

Prefac

Preface

Prefac

Erratum to: Oral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite toxoplasma gondii [corrigendum] (Int J Nanomedicine. 2015, 10, 6355–6369)

The authors have advised due to an error that occurred inadvertently at the time of figure assembly the incorrect images were selected by the first author for Figure 2 on page 6361. The correct Figure 2 is shown below. The authors apologize for this error and advise it does not affect the results and conclusions of the paper.(diagram presented)